Cargando…
A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia
Despite improvement in the long-term survival rate following pediatric acute myeloid leukemia (AML), the rate remains low, even with optimal treatment. The present study reports the long-term outcome of a small patient group treated with a single drug, high-dose chemotherapy (HDCT) with cytarabine,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618839/ https://www.ncbi.nlm.nih.gov/pubmed/36325296 http://dx.doi.org/10.3892/mco.2022.2589 |
_version_ | 1784821143632347136 |
---|---|
author | Wu, Ziliang Wu, Zelin Zou, Yawei Guan, Jingming Wu, Shangzhi Chen, Dehui |
author_facet | Wu, Ziliang Wu, Zelin Zou, Yawei Guan, Jingming Wu, Shangzhi Chen, Dehui |
author_sort | Wu, Ziliang |
collection | PubMed |
description | Despite improvement in the long-term survival rate following pediatric acute myeloid leukemia (AML), the rate remains low, even with optimal treatment. The present study reports the long-term outcome of a small patient group treated with a single drug, high-dose chemotherapy (HDCT) with cytarabine, including consolidation and maintenance therapy. RT-PCR was conducted to assess 43 fusion genes, and after treatment, all cases have been followed up for 20 years (June 2002-December 2020). With an 80% 5-year survival rate, the results of this study highlight the possibility that pediatric AML can be reasonably effectively treated with relatively simple chemotherapy when necessary. HDCT is clinically safe, effective and relatively inexpensive. We propose that in the context of limited resources, HDCT should be considered as an alternative therapy for pediatric AML. |
format | Online Article Text |
id | pubmed-9618839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-96188392022-11-01 A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia Wu, Ziliang Wu, Zelin Zou, Yawei Guan, Jingming Wu, Shangzhi Chen, Dehui Mol Clin Oncol Articles Despite improvement in the long-term survival rate following pediatric acute myeloid leukemia (AML), the rate remains low, even with optimal treatment. The present study reports the long-term outcome of a small patient group treated with a single drug, high-dose chemotherapy (HDCT) with cytarabine, including consolidation and maintenance therapy. RT-PCR was conducted to assess 43 fusion genes, and after treatment, all cases have been followed up for 20 years (June 2002-December 2020). With an 80% 5-year survival rate, the results of this study highlight the possibility that pediatric AML can be reasonably effectively treated with relatively simple chemotherapy when necessary. HDCT is clinically safe, effective and relatively inexpensive. We propose that in the context of limited resources, HDCT should be considered as an alternative therapy for pediatric AML. D.A. Spandidos 2022-10-06 /pmc/articles/PMC9618839/ /pubmed/36325296 http://dx.doi.org/10.3892/mco.2022.2589 Text en Copyright: © Wu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Wu, Ziliang Wu, Zelin Zou, Yawei Guan, Jingming Wu, Shangzhi Chen, Dehui A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia |
title | A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia |
title_full | A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia |
title_fullStr | A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia |
title_full_unstemmed | A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia |
title_short | A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia |
title_sort | clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618839/ https://www.ncbi.nlm.nih.gov/pubmed/36325296 http://dx.doi.org/10.3892/mco.2022.2589 |
work_keys_str_mv | AT wuziliang aclinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia AT wuzelin aclinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia AT zouyawei aclinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia AT guanjingming aclinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia AT wushangzhi aclinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia AT chendehui aclinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia AT wuziliang clinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia AT wuzelin clinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia AT zouyawei clinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia AT guanjingming clinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia AT wushangzhi clinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia AT chendehui clinicalreportonhighdosecytarabinetherapyforchildrenwithacutemyeloidleukemia |